<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817750</url>
  </required_header>
  <id_info>
    <org_study_id>JPJ 16/16</org_study_id>
    <nct_id>NCT02817750</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation</brief_title>
  <official_title>Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation, With Fasting and Postprandial Administration, in Male and Female Healthy Volunteers, Produced by Biolab Sanus FarmacÃªutica Ltda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biolab Sanus Farmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biolab Sanus Farmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics of the new formulation of&#xD;
      zolpidem hemitartarate orodispersible tablet 3.5 mg in male and female healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I study of zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and&#xD;
      postprandial administration. Sample size is 28 volunteers, male and female, aged from 18 to&#xD;
      50 years old.&#xD;
&#xD;
      This is an open-label, randomized, crossover study. Each volunteer will be randomized to one&#xD;
      of the following sequencies:&#xD;
&#xD;
        -  Sequency 1: zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting (period 1)&#xD;
           and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial (period 2)&#xD;
&#xD;
        -  Sequency 2: zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial (period 1)&#xD;
           and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting (period 2)&#xD;
           Formulation will be administered in a single dose, orally in each period. The volunteers&#xD;
           will be admitted in two different periods of 36 hours each, when investigational product&#xD;
           will be administered and blood samples will be collected at pre-determined periods of&#xD;
           time up to 24 hours for pharmacokinetics evaluation.&#xD;
&#xD;
      Primary objective is to evaluate the pharmacokinetics of the new formulation of zolpidem&#xD;
      hemitartarate orodispersible tablet 3.5 mg in healthy volunteers. As a secondary objective,&#xD;
      it will be evaluated if there is any pharmacokinetics difference between genders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Actual">February 22, 2018</completion_date>
  <primary_completion_date type="Actual">February 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (0-last)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (0-inf)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life (t1/2)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate constant (Ke)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum (peak) plasma concentration following drug administration (tmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vd)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (C)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of adverse events</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>zolpidem hemitartarate (fasting + post-prandial)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zolpidem hemitartarate (post-prandial + fasting)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)</intervention_name>
    <description>zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial</description>
    <arm_group_label>zolpidem hemitartarate (fasting + post-prandial)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)</intervention_name>
    <description>zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting</description>
    <arm_group_label>zolpidem hemitartarate (post-prandial + fasting)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female volunteers, aged from 18 to 50 years old (women cannot be pregnant or&#xD;
             in breastfeeding period and should be committed to use an effective contraceptive&#xD;
             method during the study)&#xD;
&#xD;
          -  Body mass index (BMI) greater than or equal to 18.5 and less than or equal to 29.9&#xD;
             kg/m2&#xD;
&#xD;
          -  Good health conditions or without significant diseases, according to best medical&#xD;
             judgment, according to medical history, blood pressure and heart rate measurements,&#xD;
             pulse, temperature, physical examination, electrocardiogram (ECG) and complementary&#xD;
             laboratory tests&#xD;
&#xD;
          -  Ability to understand the nature and objectives of the trial, including risks and&#xD;
             adverse events, willingness to cooperate with the researcher and proceed according to&#xD;
             all study requirements, which shall be confirmed by informed consent form signature.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Know hypersensitivity to the investigational product (Zolpidem) or chemically related&#xD;
             compounds&#xD;
&#xD;
          -  History or presence of hepatic or gastrointestinal diseases, or other condition that&#xD;
             interferes with drug absorption, distribution, excretion or metabolism&#xD;
&#xD;
          -  Maintenance therapy with any drugs, except oral contraceptives&#xD;
&#xD;
          -  History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic,&#xD;
             psychiatric, cardiologic or allergic diseases of any etiology , that requires&#xD;
             pharmacological treatment or considered as clinically relevant by the investigator&#xD;
&#xD;
          -  Electrocardiographic findings that at investigator discretion are not recommended for&#xD;
             study participation&#xD;
&#xD;
          -  Deviations on screening laboratory results that are considered as clinically relevant&#xD;
             by the investigator&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Intake of more than five cups of coffee or tea per day&#xD;
&#xD;
          -  History of abusive use of drugs and alcohol&#xD;
&#xD;
          -  Use of regular medication two weeks prior to study enrollment or use of any&#xD;
             medications one week prior to study enrollment&#xD;
&#xD;
          -  Hospitalization for any reasons up to 8 weeks prior to start of first period of trial&#xD;
             treatment&#xD;
&#xD;
          -  Treatment within 3 months prior to the start of trial treatment, with any drug with&#xD;
             known and well-established toxic potential to major organs&#xD;
&#xD;
          -  Participation in any pharmacokinetics trial with more than 300 mL of blood draw or&#xD;
             administration of any experimental drug within 12 months prior to trial treatment&#xD;
             start&#xD;
&#xD;
          -  Donation or loss of 450 mL or more of blood within 3 months prior to trial enrollment&#xD;
             or donation of more than 1500 mL of blood within 12 months prior to the trial&#xD;
             treatment start&#xD;
&#xD;
          -  Positive result for the BHCG urine test, performed by female subjects&#xD;
&#xD;
          -  Positive results for the detection of abusive drugs at urine exam&#xD;
&#xD;
          -  Result higher than 0.1 mg/L for the etilometer exam&#xD;
&#xD;
          -  Any condition, according to investigator's best judgment, that prevents the subject to&#xD;
             participate in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JosÃ© Pedrazzoli JÃºnior, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIFAG - Universidade Integrada de Farmacologia e Gastroenterologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNIFAG - Unidade Integrada de Farmacologia e Gastroenterologia</name>
      <address>
        <city>BraganÃ§a Paulista</city>
        <state>SP</state>
        <zip>12916-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>June 7, 2018</last_update_submitted>
  <last_update_submitted_qc>June 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

